Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse

Eur Neurol. 2012;68(1):20-2. doi: 10.1159/000337615. Epub 2012 Jun 5.

Abstract

Aim: The aim of the study was to determine the intraocular pressure (IOP) changes with high-dose intravenous methylprednisolone (HIVMP) treatment given for the treatment of acute relapses in relapsing multiple sclerosis (MS).

Methods: Forty patients with clinically definite MS admitted for a new demyelinating event were included in the study. All patients were treated with HIVMP (1 g) once daily for 5 consecutive days. IOPs of 40 patients were recorded before treatment, during the course of systemic methylprednisolone administration and at the end of each month for 3 successive months, four times a day. The average IOP of each day was statistically compared to the pretreatment value.

Results: The initial IOP was 13.5 ± 2.4 mm Hg before steroid administration. The IOP values tended to rise significantly during intravenous corticosteroid administration and in the first month of follow-up (p < 0.05). However, the increase remained within normal ranges and IOP values never exceeded 20 mm Hg during the follow-ups.

Conclusion: Our study demonstrated that MS patients treated with HIVMP have increased IOP which does not lead to conditions at risk for developing glaucoma.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Female
  • Humans
  • Infusions, Intravenous
  • Intraocular Pressure / drug effects*
  • Male
  • Methylprednisolone / administration & dosage*
  • Methylprednisolone / adverse effects
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone